Discover the latest in health: evidence‑based wellness tips, medical breakthroughs, nutrition guidance, fitness insights, and expert advice for a healthier, happier life.
Localized prostate cancer patients now have a new tool to help guide radiation therapy decisions. MiraDx, a molecular diagnostics company, has announced the U.S. Commercial launch of PROSTOX Standard, a genetic test designed to identify men at increased risk of long-term urinary side effects following conventionally fractionated or moderately hypofractionated radiation therapy (CFRT or MHFRT). This new test complements the company’s existing PROSTOX Ultra, which assesses risk for patients undergoing stereotactic body radiation therapy (SBRT).
Radiation therapy remains a cornerstone of treatment for localized prostate cancer, offering effective disease control. However, a significant proportion of men—more than 20%—experience persistent urinary side effects, known as late genitourinary (GU) toxicity, following radiation. These side effects, which can include urinary urgency, leakage, or discomfort, can significantly diminish quality of life, sometimes appearing months or even years after treatment completion. The goal of PROSTOX testing is to help physicians and patients make more informed decisions about the most appropriate course of treatment.
Understanding PROSTOX and its Role in Personalized Radiation Oncology
PROSTOX tests analyze inherited genetic variants in microRNAs and their associated pathways, offering insights into how individual patients may tolerate radiation. A simple cheek swab provides the sample needed for analysis, with results available within 5-7 days. This relatively quick turnaround time allows for timely integration of the genetic information into treatment planning. According to MiraDx, the tests are designed to bring “precision medicine to radiation oncology by shifting the focus from the tumor alone to determining the most effective treatment approach for each patient based upon their unique biology and resulting treatment risks,” as stated by Melissa C. Stoppler, MD, Executive Vice President of Medical Affairs at MiraDx.
The five-year survival rate for localized prostate cancer is exceptionally high, exceeding 99% according to the American Cancer Society. While SBRT, CFRT and MHFRT demonstrate comparable efficacy, individual responses can vary due to genetic factors. Until now, clinicians have lacked a biology-driven tool to predict which patients are most susceptible to GU toxicity from each type of radiation therapy. PROSTOX aims to fill this gap.
How PROSTOX Standard and Ultra Differ
It’s important to note that PROSTOX Standard and PROSTOX Ultra assess risk for different radiation therapy regimens. A high-risk result on PROSTOX Standard does not necessarily indicate a high-risk result on PROSTOX Ultra, and vice versa. In a little percentage of cases—less than 2% of patients—the tests may identify a high risk for late GU side effects with both SBRT and CFRT/MHFRT. For these patients, alternative interventions may be considered.
The tests provide different levels of risk assessment. PROSTOX Standard indicates that patients with a HIGH RISK result are approximately 11 times more likely to develop late grade ≥ 2 genitourinary toxicity compared to those with a LOW-AVERAGE RISK result according to MiraDx. PROSTOX Ultra shows that patients with a HIGH RISK result are around 7 times more likely to experience the same outcome compared to those with a LOW-AVERAGE RISK result.
“Being diagnosed with prostate cancer is life altering and comes with many decisions and so much uncertainty,” shared Ron Stewart, a patient who underwent PROSTOX testing. “The PROSTOX test helped me feel more confident about my treatment plan and more optimistic that my cancer treatment would not hamper my quality of life down the road.”
What’s Next for PROSTOX and Personalized Prostate Cancer Treatment?
The launch of PROSTOX Standard expands access to genetic testing for a broader range of prostate cancer patients. As research continues and more data becomes available, these types of tests are likely to play an increasingly important role in tailoring radiation therapy to individual patient needs, minimizing side effects, and improving overall quality of life. Further studies are ongoing to validate the clinical utility of PROSTOX and refine its predictive capabilities.
This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. This proves essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the role of genetic testing in cancer treatment? Share your comments below, and please share this article with anyone who might locate it helpful.